Increased risk of central line-associated bloodstream infection in COVID-19 patients associated with dexamethasone but not with interleukin antagonists

Intensive Care Med. 2022 Jul;48(7):954-957. doi: 10.1007/s00134-022-06750-w. Epub 2022 Jun 7.

Authors

Iwan A Meynaar¹, Simone van Rijn², Thomas H Ottens³, Nathalie D van Burgel⁴, Cees van Nieuwkoop⁵

Affiliations

¹ Department of Intensive Care, Haga Teaching Hospital, The Hague, Netherlands. iwanmeynaar@gmail.com.
² Department of Infection Prevention and Control, Haga Teaching Hospital, The Hague, Netherlands.
³ Department of Intensive Care, Haga Teaching Hospital, The Hague, Netherlands.
⁴ Department of Microbiology, Haga Teaching Hospital, The Hague, Netherlands.
⁵ Department of Internal Medicine, Haga Teaching Hospital, The Hague, Netherlands.

No abstract available

Publication types

Letter

MeSH terms

COVID-19 Drug Treatment*
Catheter-Related Infections* / complications
Catheterization, Central Venous* / adverse effects
Central Venous Catheters* / adverse effects
Cross Infection* / etiology
Dexamethasone / adverse effects
Humans
Interleukins
Sepsis* / complications

Substances

Interleukins
Dexamethasone